NCT01630850View on ClinicalTrials.gov

"Islet Transplantation in Patients With Brittle Type I Diabetes"

NARecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

September 30, 2025

Study Completion Date

June 30, 2030

Conditions
Diabetes Mellitus, Type 1
Interventions
BIOLOGICAL

Allogenic islet cells (human, U. Chicago)

Human allogenic islet cells. Immunosuppression may include remicade, thymoglobulin,prograf, solu-medrol, and cellcept. Dosage will vary per patient based on weight. Patients will receive immunosuppression medications while islet cells are functioning.

PROCEDURE

Intraportal infusion of islet cells

Intraportal infusion of islet cell through the portal vein in the liver.

Trial Locations (1)

60637

RECRUITING

University of Chicago Medical Center, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER